Takeda Deploys AI Across 14 Drug Programs, Cuts Drafting Time 97%

Takeda scales AI automation across global drug pipeline

Takeda Pharmaceutical has deployed an AI-driven regulatory automation platform from Weave Bio across 14 active drug development programs spanning multiple global markets. The collaboration represents one of the pharmaceutical industry's most extensive implementations of artificial intelligence in regulatory workflows to date.

The partnership initially focused on investigational new drug (IND) submissions before expanding to health authority questions (HAQ) and response-to-question (RTQ) processes. Joint research by Takeda and Weave Bio scientists documented a 97% reduction in time required to draft an initial IND submission in the evaluated use case—from approximately 100 hours down to three hours.

For HAQ and RTQ workflows, the system has processed more than 100 regulatory questions without extraction errors in the assessed dataset. The AI achieved an average answer quality score of 68%, exceeding the target range of 50-70% that Takeda had established for the deployment.

Why it matters

Regulatory submission preparation represents a significant bottleneck in drug development timelines. By compressing drafting cycles from weeks to hours while maintaining accuracy, AI automation could meaningfully accelerate time-to-market for new therapies. The scale of Takeda's deployment—14 concurrent programs—suggests the technology has moved beyond pilot phase into operational integration, potentially setting a template for industry-wide adoption as regulatory agencies clarify AI oversight frameworks.

Regulatory guardrails taking shape

The collaboration unfolds as global drug regulators establish guidelines for AI use in pharmaceutical development. The U.S. Food and Drug Administration published draft guidance on AI in regulatory decision-making in January 2025, followed by joint guiding principles from the FDA and European Medicines Agency in January 2026. Both Takeda and Weave Bio indicate their approach aligns with these emerging regulatory expectations.

"Takeda is working to become a leader in the responsible application of AI across every area of R&D, helping our teams work more effectively and accelerate the delivery of innovative medicines to patients," said Nahid Latif, Takeda's chief regulatory officer and global regulatory affairs head. She emphasized that regulatory professionals retain responsibility for content verification and final decision-making despite the AI assistance.

The regulatory guidance emphasizes safety validation and human oversight—areas where Takeda's implementation appears designed to maintain human authority over critical decisions while automating routine documentation tasks.

Broader context

The AI deployment comes as Takeda advances its broader pipeline. Last month, the company received approval from Japan's Ministry of Health, Labour and Welfare for Orzeyful (oveporexton) to treat narcolepsy type 1 in adults, demonstrating continued progress in bringing new therapies to market.

These details were first reported by Pharmaceutical Technology, a GlobalData publication.